Serum Institute seeks DCGI emergency use nod for rBCG tuberculosis vaccine

Published On 2022-03-28 06:30 GMT | Update On 2024-02-16 11:26 GMT

New Delhi: The Serum Institute has applied to the Drugs Controller General of India seeking emergency use authorisation for its recombinant BCG (rBCG) vaccine for the prevention of tuberculosis, official sources said on Sunday. The EUA application was submitted on March 22 by Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII).

India's TB immunisation programme currently offers BCG vaccination at birth or as early as possible till one year of age.

SII already supplies life-saving vaccines to the government under the Universal Immunisation Programme, including Pneumococcal, IPV and Rotavirus, Singh mentioned in his letter.

The Pune-based firm is one of the companies which supply BCG vaccine to the government.

"Our government is committed to eliminate TB. The vision of TB-free India has been energised by the clarion call of the prime minister to end TB from our country by 2025 , five years ahead of the Sustainable Development Goal of ending TB," Singh mentioned in his letter.

"Under leadership of our CEO Adar C Poonawalla, our firm is committed to make available a safe, efficacious and high-quality world class TUBERVAC-rBCG vaccine for newborns, children, adolescents and adults at affordable price," an official source quoted Singh as having said in the application.

Recombinant BCG vaccines are manufactured through advanced technology that allows the insertion of foreign genes, or overexpression of native genes, into the BCG vaccine, an official explained.

The number of tuberculosis cases in India has seen a 19 per cent rise in 2021 over the previous year, and there has been an increase in the mortality rate due to all forms of TB between 2019 and 2020 by 11 per cent, according to the annual TB report released by Union Health Minister Mansukh Mandaviya on Thursday.

Read also: SII Covovax gets DCGI emergency use nod for 12 to 18 year olds

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Serum Institute seeks DCGI emergency use nod for rBCG tuberculosis vaccine

Similar News

Wockhardt Misses NPPA Clearance for Nafithromycin, Faces Questions on Patent Validity

Ajanta Pharma Told to Revise BE Study Protocol for Cilnidipine, Metoprolol FDC

Zydus Gets CDSCO Panel Nod to Market Sodium Chloride Nebuliser Solution

SC doors knocked for child deaths linked to contaminated cough syrup, CBI probe demanded

AstraZeneca Pharma India bags CDSCO nod for expanded use of Trastuzumab Deruxtecan in HER2-Positive Solid Tumors

Coldrif Cough Syrup banned in Punjab amid child deaths

Contaminated cough syrup tragedy: NHRC steps in, demands investigation

DoP identifies 11,100 Jan Aushadhi Kendras across India as Outdoor Cleaning Sites